Update to NIH Inclusion Policy
NIH-Defined Phase III Clinical Trials
- Evidence must be reviewed to show whether clinically important sex/gender and race/ethnicity differences in intervention effect are expected
- Plans for valid analysis must be included in the design
- Results of analyses must be reported to NIH